Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnosis and Management of Mitral Valve Disease in the Elderly.

The International journal of angiology : official publication of the International College of Angiology, Inc·2025

Same author

Myocardial Infarction with Nonobstructive Coronary Artery Disease-Definition, Etiopathogenesis, Diagnosis, and Management.

The International journal of angiology : official publication of the International College of Angiology, Inc·2024

Same author

Diastolic Heart Failure Mechanisms and Assessment Revisited.

Journal of clinical medicine·2024

Same author

Contemporary Management of the Failing Fontan.

Journal of clinical medicine·2024

Same author

A case report of recurrent primary posterior mediastinal perivascular epithelioid cell tumour compressing the right inferior pulmonary vein, atria, and inferior vena cava.

European heart journal. Case reports·2024

Same author

Potential Expanded Applications of Minimally Invasive Cardiac Myectomy.

Journal of the American College of Cardiology·2023

Search research articles

Related Experiment Videos

Beta-blocker therapy for valvular disorders.

Priyanka A Desai¹, Javad Tafreshi, Ramdas G Pai

¹School of Pharmacy, Loma Linda University, Loma Linda, California 92354, USA.

The Journal of Heart Valve Disease

|July 1, 2011

Summary

This summary is machine-generated.

Beta-blockers offer benefits for valvular disorders, aiding mitral stenosis and preventing complications like atrial fibrillation. This review explores their use in severe mitral/aortic regurgitation and asymptomatic aortic stenosis.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology

Background:

Valvular heart disorders are prevalent and can mimic heart failure.
Many patients with severe valvular disease do not undergo surgery.
Beta-blockers are increasingly recognized for their role in managing these conditions.

Purpose of the Study:

To review the multifaceted roles of beta-blockers in valvular heart disease management.
To explore the potential applications of beta-blockers in specific valvular conditions and related complications.

Main Methods:

Literature review focusing on the use of beta-blockers in valvular disorders.
Analysis of evidence for beta-blocker efficacy in mitral stenosis, regurgitation, and aortic stenosis.
Examination of beta-blocker roles in preventing complications such as atrial fibrillation and aortic root dilation.

Main Results:

Beta-blockers reduce the transmitral gradient in mitral stenosis.
They can prevent atrial fibrillation and reduce valve-related hemolysis.
Potential benefits include preventing aortic root dilation in specific patient groups.

Conclusions:

Beta-blockers have a significant role in managing various valvular disorders beyond heart failure.
Their application extends to treating severe mitral regurgitation, aortic regurgitation, and asymptomatic aortic stenosis.
Further investigation into beta-blocker therapy for valvular heart disease is warranted.